[Catecholamine dependence. Pathogenesis and treatment].
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D002395:Catecholamines / Q000009:adverse effects*; D006801:Humans; D008680:Metaraminol / Q000627:therapeutic use; D008774:Methylphenidate / Q000627:therapeutic use; D009638:Norepinephrine / Q000009:adverse effects*; D010952:Plasma Substitutes / Q000627:therapeutic use; D012769:Shock / Q000188:drug therapy*; D019966:Substance-Related Disorders; D013565:Sympatholytics / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D010952:Plasma Substitutes; D013565:Sympatholytics; D008774:Methylphenidate; D008680:Metaraminol; D009638:Norepinephrine
Dipendenza catecolaminica. Patogenesi e trattamento.